July 02, 2025

Can Genetic Testing Identify the Best Treatment for Metastatic, Castration-Resistant Prostate Cancer?

Patients with metastatic, castration-resistant prostate cancer (mCRPC) have a median overall survival of only about two to three years, but genomic sequencing is making inroads against that grim prognosis.

Roswell Park Comprehensive Cancer Center

July 01, 2025

Our Vision for the Future of Cancer Care

Since 1947, Dana-Farber has been at the forefront of blending exceptional cancer care with leading-edge, transformative science. At the core of what we do is a patient-centered approach with a singular focus — cancer care.

Dana-Farber

July 01, 2025

Survey Shows Inaccuracies in U.S. Perceptions of Testicular Cancer

Only about 13% of U.S. adults correctly reported that testicular cancer is most common among men younger than 40.

The ASCO Post

July 01, 2025

New Study Shows Tiny Cuts Could Improve Brain Surgery: A Simpler, Safer Way to Treat Brain Tumors

A new study from doctors at Miami Neuroscience Institute, part of Baptist Health, highlights a gentler way to perform brain surgery, one that uses small tools and avoids the need for large openings in the skull.

Baptist Health South Florida

June 30, 2025

Cellular Therapies Leading to New Treatment Options for Lymphoma Patients

A new CAR T-cell consortium, Matthew Cortese, MD, MPH, a hematologic oncologist at Roswell Park Comprehensive Cancer Center, shares that certain types of hard-to-treat lymphomas may be more receptive to immunotherapies than previously thought.

Roswell Park Comprehensive Cancer Center

June 30, 2025

Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer

Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete...

The ASCO Post

June 30, 2025

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cell therapy and survival in patients with colorectal cancer.

The ASCO Post

June 30, 2025

Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer

Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluor...

The ASCO Post

June 30, 2025

Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer

For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly impr...

The ASCO Post